Socioeconomic factors likely contribute to racial and ethnic disparities in health care utilization among patients with ...

Spyre Therapeutics, Inc.’s SYRE share price has surged by 6.55%, which has investors questioning if this is right time to ...

Viking Therapeutics has multiple promising drugs in its portfolio that could generate billions in future revenue. Approval of VK2735 and VK2809 could lead to a surge in the stock's value.

Spyre Therapeutics has a 52 week low of $10.91 and a 52 week high of $40.84. The company has a market cap of $805.64 million, a PE ratio of -1.79 and a beta of 3.05.

Spyre Therapeutics has a fifty-two week low of $11.46 and a fifty-two week high of $40.84. Spyre Therapeutics ( NASDAQ:SYRE – Get Free Report ) last issued its earnings results on Thursday ...

Analyst Price Forecast Suggests 353.70% Upside As of April 2, 2025, the average one-year price target for Spyre Therapeutics is $56.21/share. The forecasts range from a low of $27.27 to a high of ...

7 analysts have shared their evaluations of Voyager Therapeutics VYGR during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise ...

Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in ...

WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...